226.85
-1.14
(-0.50%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 224.60 - 228.86 |
| 52 week | 126.39 - 231.99 |
| Open | 228.36 |
| Vol / Avg. | 1.24M/1.33M |
| Mkt cap | 53.85B |
| P/E | 36.02 |
| Div/yield | - |
| EPS | 6.30 |
| Shares | 237.37M |
| Beta | 0.91 |
| Inst. own | 95% |
Events
Jul 22, 2013
Q2 2013 Biogen Idec Inc. Earnings Release
Jun 12, 2013
Biogen Idec Inc. Annual Shareholder Meeting
- 9:00AM EDT -
Apr 29, 2013
Q1 2013 Biogen Idec Inc. Earnings Release
Apr 25, 2013
Q1 2013 Biogen Idec Inc. Earnings Conference Call -
Apr 23, 2013
Biogen Idec Inc. at Biotechnology Industry Organization (BIO) International Convention
Mar 4, 2013
Biogen Idec Inc. at Cowen Health Care Conference -
Feb 26, 2013
Biogen Idec Inc. at RBC Capital Markets' Healthcare Conference -
Feb 25, 2013
Biogen Idec Inc. at Citi Global Healthcare Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 30.43% | 25.10% |
| Operating margin | 36.06% | 33.54% |
| EBITD margin | - | 39.48% |
| Return on average assets | 17.02% | 14.44% |
| Return on average equity | 23.94% | 20.62% |
| Employees | 5,950 | - |
| Carbon Disclosure Rating | - | 84/100 |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Transcripts - SeekingAlpha
About Company - Wikipedia
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company�s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.
Officers and directors
| William D. Young | Independent Chairman of the Board | |
| George A. Scangos Ph.D. | Chief Executive Officer, Director | |
| Paul J. Clancy | Chief Financial Officer, Executive Vice President - Finance | |
| Kenneth A. Di Pietro | Executive Vice President - Human Resources | |
| Susan H. Alexander Esq. | Executive Vice President, Chief Legal Officer and Corporate Secretary | |
| John G. Cox | Executive Vice President - Pharmaceutical Operations and Technology | |
| Steven H. Holtzman | Executive Vice President - Corporate Development | |
| Tony Kingsley | Executive Vice President - Global Commercial Operations | |
| Douglas E. Williams Ph.D. | Executive Vice President - Research and Development | |
| Ray Pawlicki | Senior Vice President, Chief Information Officer |